Ownership / Teva Pharmaceutical Industries Limited | Tables in SEC filings

TEVA Teva Pharmaceutical Industries Limited

Quarterly report

	September 30,			December 31,
	2024			2023
ASSETS		Current assets:		Cash and cash equivalents		$	3,319		$	3,226
Accounts receivables, net of allowance for credit losses of $91 million and $95 million as of September 30, 2024 and December 31, 2023		3,462			3,408
Inventories		3,959			4,021
Prepaid expenses		1,127			1,255
Other current assets		445			504
Assets held for sale		2			70

Total current assets		12,314			12,485
Deferred income taxes		2,070			1,812
Other non-current assets		459			470
Property, plant and equipment, net		5,672			5,750
Operating lease right-of-use assets, net		364			397
Identifiable intangible assets, net		4,756			5,387
Goodwill		16,124			17,177

Total assets	$	41,758		$	43,479

LIABILITIES AND EQUITY		Current liabilities:		Short-term debt		$	2,580		$	1,672
Sales reserves and allowances		3,785			3,535
Accounts payables		2,371			2,602
Employee-related obligations		619			611
Accrued expenses		2,984			2,771
Other current liabilities		1,241			1,044
Liabilities held for sale		216			13

Total current liabilities		13,797			12,247
Long-term liabilities:		Deferred income taxes		538				606
Other taxes and long-term liabilities		4,344			4,019
Senior notes and loans		16,400			18,161
Operating lease liabilities		295			320

Total long-term liabilities		21,578			23,106

Commitments and contingencies , see note 10			Total liabilities			35,375			35,353

Equity:		Teva shareholders’ equity:		Ordinary shares of NIS 0.10 par value per share; September 30, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,240 million shares and 1,227 million shares, respectively			58			57
Additional paid-in capital		27,860			27,807
Accumulated deficit		(14,956)			(13,534)
Accumulated other comprehensive loss		(2,769)			(2,697)
Treasury shares as of September 30, 2024 and December 31, 2023: 106 million ordinary shares		(4,128)			(4,128)

	6,065			7,506

Non-controlling interests		319			620

Total equity		6,383			8,126

Total liabilities and equity	$	41,758		$	43,479

	September 30, 2023
	As previously reported			Adjustment		As revised
	(Unaudited)
Deferred income taxes	$	1,748			7		1,755
Total assets		42,088			7		42,095
Other taxes and long-term liabilities		3,818			132		3,950
Total long-term liabilities		23,182			132		23,314
Total liabilities		34,576			132		34,708
Teva shareholders’ equity:			Accumulated deficit		(13,870)		(125)	(13,995)
Total equity		7,512			(125)		7,387
Total liabilities and equity	$	42,088			7		42,095

	Interest rate as of September 30, 2024				Maturity				September 30, 2024		December 31, 2023
									(U.S. $ in millions)
Senior notes USD 1,250 million (4)		6.00	%			2024				—		956
Senior notes EUR 1,500 million (5)		1.13	%			2024				700		693
Senior notes EUR 1,000 million		6.00	%			2025				459		453
Senior notes USD 1,000 million		7.13	%			2025				427		427
Senior notes EUR 900 million		4.50	%			2025				554		547
Senior notes CHF 350 million		1.00	%			2025				417		416
Senior notes USD 3,500 million		3.15	%			2026				3,374		3,374
Senior notes EUR 700 million		1.88	%			2027				781		771
Sustainability-linked senior notes USD 1,000 million (1)(*)		4.75	%			2027				1,000		1,000
Sustainability-linked senior notes EUR 1,100 million (1)(*)		3.75	%			2027				1,229		1,215
Senior notes USD 1,250 million		6.75	%			2028				1,250		1,250
Senior notes EUR 750 million		1.63	%			2028				834		826
Sustainability-linked senior notes USD 1,000 million (2)(*)		5.13	%			2029				1,000		1,000
Sustainability-linked senior notes USD 600 million (3)(*)		7.88	%			2029				600		600
Sustainability-linked senior notes EUR 800 million (3)(*)		7.38	%			2029				895		884
Sustainability-linked senior notes EUR 1,500 million (2)(*)		4.38	%			2030				1,676		1,656
Sustainability-linked senior notes USD 500 million (3)(*)		8.13	%			2031				500		500
Sustainability-linked senior notes EUR 500 million (3)(*)		7.88	%			2031				558		552
Senior notes USD 789 million		6.15	%			2036				783		783
Senior notes USD 2,000 million		4.10	%			2046				1,986		1,986

Total senior notes				19,023				19,889
Other long-term debt				2				1
Less current maturities				(2,557)				(1,649)
Less debt issuance costs				(68)				(80)

Total senior notes and loans			$	16,400			$	18,161

	Financial expenses, net				Other comprehensive income (loss)
	Three months ended,				Three months ended,
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Reported under	(U.S. $ in millions)
Line items in which effects of hedges are recorded	$	272	$	280	$	180	$	(249)
Cross-currency swaps - cash flow hedge (1)		—		(7)		—		1
	Financial expenses, net				Other comprehensive income (loss)
	Nine months ended,				Nine months ended,
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Reported under	(U.S. $ in millions)
Line items in which effects of hedges are recorded	$	763	$	808	$	(75)	$	(156)
Cross-currency swaps - cash flow hedge (1)		(8)		(22)		1		(4)


	Three months ended						Nine months ended
	September 30,						September 30,
	2024			2023			2024			2023
	(U.S. $ in millions)						(U.S. $ in millions)
United States profit	$	748		$	571		$	1,727		$	1,421
Europe profit		373			338			1,137			1,017
International Markets profit		109			117			299			356

Total reportable segments profit		1,230			1,025			3,163			2,794
Profit (loss) of other activities		(16)			(5)			(1)			22

Total segments profit		1,214			1,020			3,162			2,816
Amounts not allocated to segments:			Amortization			146			145			444	471
Other assets impairments, restructuring and other items*		(23)			57			931			276
Goodwill impairment		600			—			1,000			700
Intangible assets impairments		28			47			169			289
Legal settlements and loss contingencies		450			314			638			1,009
Other unallocated amounts		64			112			254			394

Consolidated operating income (loss) *		(51)			344			(274)			(323)

Financial expenses, net		272			280			763			808

Consolidated income (loss) before income taxes *	$	(324)		$	64		$	(1,037)		$	(1,131)

Table search / Ownership / Teva Pharmaceutical Industries Limited

284 results

Top filers

Top filing types

Recent filing years